A pre-specified analysis of the SELECT trial assessing whether once-weekly semaglutide 2.4 mg improves kidney outcomes in adults with overweight or obesity and cardiovascular disease, without diabetes. PICO summary and expert commentary.
Browsing: Obesity & Weight Management
Evidence summaries for obesity and weight management, including lifestyle trials, pharmacotherapy, bariatric/metabolic outcomes, cardiometabolic risk, and long-term safety.
A prespecified secondary analysis of the STEP-HFpEF programme found that once-weekly semaglutide 2.4 mg lowered NT-proBNP and produced larger symptom gains in patients with higher baseline NT-proBNP. PICO summary and expert commentary.
Pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials of semaglutide 2.4 mg in obesity-related HFpEF, with PICO summary and expert commentary.
Post hoc analysis of the STEP 1, 2, 3, and 5 trials finds semaglutide 2.4 mg did not increase depression or suicidal ideation versus placebo in people without major psychopathology. PICO summary and expert commentary.
Clinical Context Prediabetes affects approximately 96 million American adults—more than one-third of the adult population—and represents a critical window for…
Summary: In adults with obesity-related HFpEF (BMI ≥30) from pooled STEP-HFpEF trials (n=1,145), stratified by baseline diuretic use, once-weekly semaglutide…
Prespecified subgroup analysis of the pooled STEP-HFpEF Program testing whether atrial fibrillation modifies semaglutide’s effect on symptoms in obesity-related HFpEF. PICO summary and expert commentary.
An echocardiography substudy of the STEP-HFpEF Program found once-weekly semaglutide 2.4 mg attenuated adverse cardiac remodeling versus placebo over 52 weeks. PICO summary and expert commentary.
A pooled secondary analysis of the STEP-HFpEF and STEP-HFpEF DM trials examined whether baseline atrial fibrillation modified the benefit of once-weekly semaglutide 2.4 mg in obesity-related HFpEF. PICO summary and expert commentary.
Pooled patient-reported outcomes from the STEP 1-4 trials show semaglutide 2.4 mg improved physical functioning versus placebo over 68 weeks. PICO summary and expert commentary.